There are presently no vacancies at Dendrite Clinical Systems.
----------------------------------------------------------------------------------------------------------------------------------------------------------
Dendrite Clinical Systems is always looking to recruit innovative and creative individuals, who want to bring new ideas to the table.
We are always keen to meet energetic and ambitious professionals who would like to join our team. If you wish to be considered for any future positions, please send your CV and covering letter to: jobs@e-dendrite.com
Please note, it is our standard policy to recruit independently, however, where this is not possible, we work with a number of carefully selected recruitment agencies. We are not looking to add to this roster, so please do not contact us if our details are not on your system.
There are currently no positions available at Dendrite Clinical Systems, please check back regularly for up-dates.
Dendrite Clinical Systems is an Equal Opportunity Employer and does not discriminate in employment on the basis of race, colour, ethnic origin, religion, sex (including pregnancy and gender identity), national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, membership in an employee organisation, retaliation, parental status, military service or other non-merit factor.
Dendrite Clinical Systems is delighted to report that our Managing Director, Dr Peter Walton, has published a chapter discussing the value of clinical registries in new publication on Laparoscopic Sleeve Gastrectomy (LSG). In his Chapter, Dr Peter Walton outlines value of national bariatric registries and their capability to deliver evidence on a global basis, as well as providing some practical perspectives on best practice when setting out to start a national registry and how to keep a good registry going.
Dendrite Clinical Systems and the Institute for Health Research (IGES) in Berlin, Germany, have initiated the Outpatient Treatment of COVID-19 Infections (ABC-19) study, to record data on the treatment of COVID-19 patients and discover more about the outpatient course of the disease, the individual risk factors of patients that contribute to severe COVID-19 courses and the procedures of general practitioners (GPs).
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19.


